These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 27738913)

  • 1. Strategies for the Discovery and Development of New Antibiotics from Natural Products: Three Case Studies.
    Herrmann J; Lukežič T; Kling A; Baumann S; Hüttel S; Petković H; Müller R
    Curr Top Microbiol Immunol; 2016; 398():339-363. PubMed ID: 27738913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
    Ganihigama DU; Sureram S; Sangher S; Hongmanee P; Aree T; Mahidol C; Ruchirawat S; Kittakoop P
    Eur J Med Chem; 2015 Jan; 89():1-12. PubMed ID: 25462220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives in drug discovery against tuberculosis from natural products.
    Nguta JM; Appiah-Opong R; Nyarko AK; Yeboah-Manu D; Addo PG
    Int J Mycobacteriol; 2015 Sep; 4(3):165-83. PubMed ID: 27649863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural antimicrobial peptides against Mycobacterium tuberculosis.
    Abedinzadeh M; Gaeini M; Sardari S
    J Antimicrob Chemother; 2015 May; 70(5):1285-9. PubMed ID: 25681127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target discovery focused approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products.
    Baptista R; Bhowmick S; Nash RJ; Baillie L; Mur LA
    Future Med Chem; 2018 Apr; 10(7):811-822. PubMed ID: 29569936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
    Farah SI; Abdelrahman AA; North EJ; Chauhan H
    Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The re-emerging role of microbial natural products in antibiotic discovery.
    Genilloud O
    Antonie Van Leeuwenhoek; 2014 Jul; 106(1):173-88. PubMed ID: 24923558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.
    Kling A; Lukat P; Almeida DV; Bauer A; Fontaine E; Sordello S; Zaburannyi N; Herrmann J; Wenzel SC; König C; Ammerman NC; Barrio MB; Borchers K; Bordon-Pallier F; Brönstrup M; Courtemanche G; Gerlitz M; Geslin M; Hammann P; Heinz DW; Hoffmann H; Klieber S; Kohlmann M; Kurz M; Lair C; Matter H; Nuermberger E; Tyagi S; Fraisse L; Grosset JH; Lagrange S; Müller R
    Science; 2015 Jun; 348(6239):1106-12. PubMed ID: 26045430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural products as leads for tuberculosis drug development.
    Salomon CE; Schmidt LE
    Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.
    Biecker AL; Liu X; Thorson JS; Yang Z; Van Lanen SG
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30691073
    [No Abstract]   [Full Text] [Related]  

  • 12. New Griselimycins for Treatment of Tuberculosis.
    Holzgrabe U
    Chem Biol; 2015 Aug; 22(8):981-2. PubMed ID: 26295835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity.
    Baumann S; Herrmann J; Raju R; Steinmetz H; Mohr KI; Hüttel S; Harmrolfs K; Stadler M; Müller R
    Angew Chem Int Ed Engl; 2014 Dec; 53(52):14605-9. PubMed ID: 25510965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens.
    Hüttel S; Testolin G; Herrmann J; Planke T; Gille F; Moreno M; Stadler M; Brönstrup M; Kirschning A; Müller R
    Angew Chem Int Ed Engl; 2017 Oct; 56(41):12760-12764. PubMed ID: 28730677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities for natural products in 21
    Wright GD
    Nat Prod Rep; 2017 Jul; 34(7):694-701. PubMed ID: 28569300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
    Kigondu EM; Wasuna A; Warner DF; Chibale K
    Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a new class of tetracycline lead structures with potent antibacterial activity through biosynthetic engineering.
    Lešnik U; Lukežič T; Podgoršek A; Horvat J; Polak T; Šala M; Jenko B; Harmrolfs K; Ocampo-Sosa A; Martínez-Martínez L; Herron PR; Fujs Š; Kosec G; Hunter IS; Müller R; Petković H
    Angew Chem Int Ed Engl; 2015 Mar; 54(13):3937-40. PubMed ID: 25650563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural products in drug discovery: present status and perspectives.
    Molinari G
    Adv Exp Med Biol; 2009; 655():13-27. PubMed ID: 20047031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Products as a Source for Novel Antibiotics.
    Moloney MG
    Trends Pharmacol Sci; 2016 Aug; 37(8):689-701. PubMed ID: 27267698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.